Senores Pharma: Mr. Vinay Kumar Mishra ceases as Company Secretary & Compliance Officer on June 10, 2026
Senores Pharmaceuticals Limited announced that Mr. Vinay Kumar Mishra will cease as Company Secretary and Compliance Officer effective June 10, 2026. Mr. Swapnil Jatinbhai Shah and Mr. Deval Rajnikant Shah are authorized for disclosures.
The departure of a Company Secretary and Compliance Officer is a standard corporate event. The company has designated other Key Managerial Personnel to handle disclosures, minimizing operational impact.
The announcement pertains to the cessation of a key managerial personnel, which is a routine corporate event. While it follows a resignation, there are no immediate positive or negative financial implications mentioned.
Senores Pharmaceuticals Limited has announced the cessation of Mr. Vinay Kumar Mishra as the Company Secretary and Compliance Officer. He will be relieved from his duties and responsibilities effective from the closure of business hours on June 10, 2026.
This follows an earlier intimation dated May 14, 2026, regarding his resignation. In accordance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Swapnil Jatinbhai Shah, Managing Director, and Mr. Deval Rajnikant Shah, Whole Time Director and Chief Financial Officer, are authorized to determine the materiality of events and make disclosures to the stock exchanges.
The company has already provided the requisite information as per SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, along with Mr. Mishra's resignation letter, in their previous intimation on May 14, 2026.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.